Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- The WHO, IFPMA to Cooperate to Combat Counterfeit Drugs
April 3, 2006
- Korosho to Standardize Package Inserts for Generics
April 3, 2006
- REGULATORY NEWS IN BRIEF
April 3, 2006
- Shift to Low-priced Drugs Could Weaken Wholesalers: FJPWA
April 3, 2006
- SELF-MEDICATION NEWS IN BRIEF
April 3, 2006
- HUMAN RESOURCES NEWS IN BRIEF
April 3, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 3, 2006
- STATISTICS
April 3, 2006
- MEDICAL DEVICE NEWS IN BRIEF
April 3, 2006
- Takeda to Emphasize Concept-based R&D Model
April 3, 2006
- SURVEY 2 articles
April 3, 2006
- Astellas Licenses Anti-Human Osteopontin Antibodies from IBL
April 3, 2006
- Eli Lilly to Enter GP Market with Tadalafil: President Crenshaw
April 3, 2006
- Toyama's T-705 Effective Against Avian Flu in Early Testing
April 3, 2006
- US Subsidiaries of Daiichi, Sankyo to Integrate Operations
April 3, 2006
- Janus Initiates PII Trial of Topical Herpes Zoster Treatment in US
April 3, 2006
- Worldwide Production of Tamiflu Expanded to 400 Mil. Treatments: Chugai
April 3, 2006
- CytoPathfinder, Santen to Do Joint Research for Ophthalmic Drugs
April 3, 2006
- BUSINESS NEWS IN BRIEF
April 3, 2006
- Taiyo to Independently Supply All Specifications
March 27, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…